Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79862.930.028%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

UroGen Pharma Ltd

URGNNASDAQ
Trade with Public
Trade with Public
$44.09
-0.79-1.76%
At close: Sep 4, 5:00 PM EST
$44.09
N/A
After Hours: Sep 4, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

UroGen Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for UroGen Pharma (URGN).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

7Buy
1Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$39Upside to Avg. PT-12.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2026GuggenheimMichael SchmitzPT RaiseBuy$42→$58
Aug 6, 2026HC Wainwright & Co.Raghuram SelvarajuPT RaiseBuy$45→$75
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $45 to $75.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $50 to $60.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50

Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and raises the price target from $40 to $50.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $45 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved